Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire N Harrison

Showing results (1-10 of 201) with videos related to

Pageof 21
Sort By:
Hemasphere|October 16, 2024
Are we ready for disease modification in myeloproliferative neoplasms?Claire N Harrison
British Journal of Haematology|June 13, 2002
Current trends in essential thrombocythaemiaClaire N Harrison
British Journal of Haematology|July 21, 2005
Essential thrombocythaemia: challenges and evidence-based managementClaire N Harrison
Hematology. American Society of Hematology. Education Program|November 24, 2005
Platelets and thrombosis in myeloproliferative diseasesClaire N Harrison
Seminars in Thrombosis and Hemostasis|May 5, 2006
Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trialClaire N Harrison
Blood|March 29, 2014
Increasing therapeutic efficacy in MPNClaire N Harrison
Journal of Medical Economics|February 19, 2016
JAK inhibitors truly changing the therapeutic paradigm in myelofibrosisClaire N Harrison
Future Oncology (London, England)|March 25, 2006
Anagrelide for control of thrombocytosis due to myeloproliferative disordersClaire N Harrison
Journal of Clinical Pathology|August 4, 2017
Hb Baden: a rare high affinity haemoglobin variant and its managementJoe Lee, Claire N Harrison
Clinical Laboratory|April 13, 2004
Risk factors for thrombosis in essential thrombocythaemiaBetty Cheung, Claire N Harrison
Pageof 21

Showing results (1-10 of 201) with videos related to

Sort By:
Pageof 21
Hemasphere|October 16, 2024
Are we ready for disease modification in myeloproliferative neoplasms?Claire N Harrison
British Journal of Haematology|June 13, 2002
Current trends in essential thrombocythaemiaClaire N Harrison
British Journal of Haematology|July 21, 2005
Essential thrombocythaemia: challenges and evidence-based managementClaire N Harrison
Hematology. American Society of Hematology. Education Program|November 24, 2005
Platelets and thrombosis in myeloproliferative diseasesClaire N Harrison
Seminars in Thrombosis and Hemostasis|May 5, 2006
Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trialClaire N Harrison
Blood|March 29, 2014
Increasing therapeutic efficacy in MPNClaire N Harrison
Journal of Medical Economics|February 19, 2016
JAK inhibitors truly changing the therapeutic paradigm in myelofibrosisClaire N Harrison
Future Oncology (London, England)|March 25, 2006
Anagrelide for control of thrombocytosis due to myeloproliferative disordersClaire N Harrison
Journal of Clinical Pathology|August 4, 2017
Hb Baden: a rare high affinity haemoglobin variant and its managementJoe Lee, Claire N Harrison
Clinical Laboratory|April 13, 2004
Risk factors for thrombosis in essential thrombocythaemiaBetty Cheung, Claire N Harrison
Pageof 21